1-3 of 3
Lisa Jackson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.

Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Klaus Hollmig, Lisa Jackson, Joshua Epstein, John Shaughnessy, John Crowley, Bart Barlogie
Journal: Blood
Blood (2005) 106 (11): 423.
https://doi.org/10.1182/blood.V106.11.423.423
Published: 2005
Journal Articles

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

John Shaughnessy, PhD, Frank Zhan, PhD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Lisa Jackson, Athanasios Fassas, MD, Maurizio Zangari, MD, Choon-Kee Lee, MD, Giampaolo Talamo, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 4935.
https://doi.org/10.1182/blood.V104.11.4935.4935
Published: 2004
Journal Articles

Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities.

Bart Barlogie, MD, PhD, Klaus Hollmig, MD, Maurizio Zangari, MD, Julie Stover, Lisa Jackson, Teresa Milner, Athanasios Fassas, MD, Guido Tricot, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 538.
https://doi.org/10.1182/blood.V104.11.538.538
Published: 2004